pmid,title,journal,year,drug,disease
37842172,"Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study.",EClinicalMedicine,2023,Tofacitinib,Parkinson's
36270334,Infliximab and Tofacitinib Attenuate Neutralizing Antibody Responses Against SARS-CoV-2 Ancestral and Omicron Variants in Inflammatory Bowel Disease Patients After 3 Doses of COVID-19 Vaccine.,Gastroenterology,2023,Tofacitinib,Parkinson's
36088954,"COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study.",The lancet. Gastroenterology & hepatology,2022,Tofacitinib,Parkinson's
35366203,"Protective Effect of CP690550 in MPTP-Induced Parkinson's Like Behavioural, Biochemical and Histological Alterations in Mice.",Neurotoxicity research,2022,Tofacitinib,Parkinson's
35123676,"COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study.",The lancet. Gastroenterology & hepatology,2022,Tofacitinib,Parkinson's
